TME Pharma N.V. ALTME

TME PHARMA CEO MESSAGE Berlin, Germany, September 16, 2026, 8.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, today publishes a message from its CEO for the shareholders. Dear Shareholders,As I look back on the recent period, one clear feeling dominates: remained confidence in the path we are taking. We fully understand that many of you are eager to see concrete

TME Pharma provides update on its activities TME Pharma enters the final evaluation phase of advanced discussions with two potential partners for a license agreement.Discussions and potential partnership are aimed at enabling the further development of the phase2-development of flagship product NOX-A12.NOX-A12 holds FDA and EU Orphan Drug and FDA Fast Track designations in glioblastoma, supported by recent peer-reviewed publication in Nature Communications.With estimated yearly peak sales potent

Minutes of the TME Pharma Annual General Meeting Berlin, Germany, June 17, 2026, 6:30 p.m. CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, today announced that all resolutions were adopted at the meeting held on June 15. The Annual General Meeting of TME Pharma shareholders was held on Monday, June 15, 2026, chaired by Mr. Diede van den Ouden. Four shareholders were

TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS Berlin, Germany, May 21, 2026, 18.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases (TME), announces today that the annual general meeting of shareholders (AGM) of the company is convened at 10.00 a.m. CEST on 15 June 2026 at Sheraton Amsterdam Airport Hotel & Conference Center, Sch

TME Pharma publishes its annual financial results and annual report Berlin, Germany, April 30, 2026, 20.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, announces today its financial results for the fiscal year ending December 31, 2025. The Annual Report 2025, as approved by the management and supervisory boards on April 30, 2025, is available on TME Pharma’s web

TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Berlin, Germany, April 16, 2026, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for braincancer and eye diseases, is pleased to announce a Nature Communications article on the results from the Phase 1/2 expansion Arm A cohort of the GLORIA trial testing NO

TME Pharma extends financial runway to over 12 months Berlin, Germany, March 9, 2025, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased to announce that certain lenders have accepted to extend the maturity of their loan by a further 12 months. TME Pharma now has cash runway into Q2 2027. An agreement has been reached with certain lenders who participated i